• 1
    Centers for Disease Control and Prevention. CDC WONDER Compressed Mortality Database 1999. Available at: Accessed April 23, 2003.
  • 2
    Hardcastle JD, Chamberlain JO, Robinson MH, et al. Randomized controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet. 1996;348: 14727.
  • 3
    Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard O. Randomized study of screening for colorectal cancer with fecal-occult-blood test. Lancet. 1996;348: 146771.
  • 4
    Mandel JS, Bond JH, Church TR, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med. 1993;328: 136571.
  • 5
    Mandel JS, Church TR, Bond JH, et al. The effect of fecal occult blood screening on the incidence of colorectal cancer. N Engl J Med. 2000;343: 16037.
  • 6
    Centers for Disease Control and Prevention. State- and sex-specific prevalence of selected characteristics — Behavior Risk Factor Surveillance System, 1996 and 1997. MMWR Morb Mortal Wkly Rep. 2000;49: 139.
  • 7
    Sharma VK, Vasudeva R, Howden CW. Colorectal cancer screening and surveillance practices by primary care physicians: results of a national survey. Am J Gastroenterol. 2000;95: 15516.
    Direct Link:
  • 8
    U.S. Preventive Services Task Force. Guide to clinical preventive services: Report of the U.S. Preventive Services Task Force. 2nd ed. Baltimore, Md: Williams and Wilkins; 1996: 89103.
  • 9
    Byers T, Levin B, Rothenberger D, Dodd GD, Smith RA. American Cancer Society guidelines for screening and surveillance for early detection of colorectal polyps and cancer: update 1997. American Cancer Society Detection and Treatment Advisory Group on Colorectal Cancer. CA Cancer J Clin. 1997;47: 15460.
  • 10
    Myers RE, Hyslop T, Gerrity M, et al. Physician intention to recommend complete diagnostic evaluation in colorectal cancer screening. Cancer Epidemiol Biomarkers Prevent. 1999;8: 58793.
  • 11
    Azjen I, Fishbein M. Understanding, Attitudes, and Predicting Social Behavior. Englewood Cliffs, NJ: Prentice-Hall; 1980.
  • 12
    Bandura A. Social Foundations of Thought and Action: A Social Cognitive Theory. Englewood Cliffs, NJ: Prentice-Hall; 1986.
  • 13
    Myers RE, Fishbein G, Hyslop T, et al. Measuring complete diagnostic evaluation in colorectal cancer screening. Cancer Detect Prev. 2001;25: 17482.
  • 14
    Shields HM, Weiner MS, Henry DR, et al. Factors that influence the decision to do an adequate evaluation of a patient with a positive stool for occult blood. Am J Gastroenterol. 2001;96: 196203.
    Direct Link:
  • 15
    Lieberman D. Screening/early detection model for colorectal cancer. Why screen? Cancer. 1994;74: 20237.
  • 16
    Mandelblatt J, Andrews H, Kao R, Wallace R, Kerner J. The late-stage diagnosis of colorectal cancer: demographic and socioeconomic factors. Am J Public Health. 1996;86: 17947.
  • 17
    Donovan JM, Syngal S. Colorectal cancer in women: an under-appreciated but preventable risk. J Womens Health. 1998;7: 458.
  • 18
    Erblich J, Bovbjerg DH, Norman C, Valdimarsdottir HB, Montgomery GH. It won't happen to me: lower perception of heart disease risk among women with family histories of breast cancer. Prev Med. 2000;31: 71421.
  • 19
    Mandelson MT, Curry SJ, Anderson LA, et al. Colorectal cancer screening participation by older women. Am J Prev Med. 2000;19: 14954.
  • 20
    Richards C, Klabunde C, O'Malley M. Physicians' recommendations for colon cancer screening in women. Too much of a good thing? Am J Prev Med. 1998;15: 2469.
  • 21
    Schulman KA, Berlin JA, Harless W, et al. The effect of race and sex on physicians' recommendations for cardiac catheterization. N Engl J Med. 1999;340: 61826.
  • 22
    Daly SC, Roger VL, Leibson C, et al. Cardiology services after stress testing: are there sex differences? A population-based study. J Clin Epidemiol. 2000;53: 6618.
  • 23
    Turner BJ, Markson LE, Mc Kee LJ, Houchens R, Fanning T. Health care delivery, zidovudine use, and survival of women and men with AIDS. J Acquir Immune Defic Syndr. 1994;7: 125062.
  • 24
    Mocroft A, Gill MJ, Davidson W, Phillips AN. Are there gender differences in starting protease inhibitors, HAART, and disease progression despite equal access to care? J Acquir Immune Defic Syndr. 2000;24: 47582.
  • 25
    Arfken CL, Borisova N, Klein C, di Menza S, Schuster CR. Women are less likely to be admitted to substance abuse treatment within 30 days of assessment. J Psychoactive Drugs. 2002;34: 338.
  • 26
    Pignone M, Rich M, Teutsch SM, Berg AO, Lohr KN. Screening for colorectal cancer in adults at average risk: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2002;137: 13241.
  • 27
    Nikolajevic-Sarunac J, Henry DA, O'Connell DL, Robertson J. Effects of information framing on the intentions of family physicians to prescribe long-term hormone replacement therapy. J Gen Intern Med. 1999;14: 5918.
  • 28
    Borum ML. Cancer screening in women by internal medicine resident physicians. South Med J. 1997;90: 11015.
  • 29
    Massari V, Retel O, Flahault A. How do general practitioners approach hepatitis C virus screening in France? Eur J Epidemiol. 1999;15: 11924.
  • 30
    Fender GR, Prentice A, Gorst T, et al. Randomised controlled trial of educational package on management of menorrhagia in primary care: the Anglia menorrhagia education study. BMJ. 1999;318: 124650.
  • 31
    Block B, Branham RA. Efforts to improve the follow-up of patients with abnormal Papanicolaou test results. J Am Board Fam Pract. 1998;11: 779.
  • 32
    Mc Carthy BD, Yood MU, Janz NK, Boohaker EA, Ward RE, Johnson CC. Evaluation of factors potentially associated with inadequate follow-up of mammographic abnormalities. Cancer. 1996;77: 20706.
  • 33
    Thomson-O'Brien MA, Oxman AD, Davis DA, Haynes RB, Freemantle N, Harvey EL. Educational outreach visits: effects on professional practice and health care outcomes. Cochrane Database Syst Rev. 2000;2: CD000409.